Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MO-TRANS phase III trial of mocravimod after allogeneic HCT in AML
jRCT2011230008Phase 3Recruiting
- Sponsor
- Priothera
- Start
- Feb 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of mocravimod in acute myeloid leukemia (AML) (3 arms), sponsored by Priothera. Primary endpoint: Relapse-Free Survival. Started Feb 2024; status: recruiting.
02
Drugs
mocravimod
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2011230008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230008.